Uvea Melanoma – Comprehensive Medical Guide

Overview

Uvea melanoma (also called choroidal melanoma when it originates in the choroid, the largest part of the uvea) is a rare, malignant tumor arising from melanocytes—pigment‑producing cells—within the uveal tract of the eye. The uvea consists of three structures: the choroid, ciliary body, and iris. Melanoma can develop in any of these locations, but >90 % arise in the choroid.

While melanoma is most often discussed in relation to the skin, uveal melanoma is the most common primary intra‑ocular malignancy in adults.

• Incidence: Approximately 5–7 cases per million people per year in the United States, translating to ~1,200 new diagnoses annually.
• Age: Median age at diagnosis is 55–65 years; it is uncommon in people under 20.
• Gender: Slight male predominance (≈55 % men).
• Ethnicity: Much more frequent in individuals of Caucasian descent; rare in African, Asian, and Hispanic populations.

Uveal melanoma can metastasize, most often to the liver, and metastatic disease is the leading cause of death from this cancer.

Symptoms

Because the eye is a closed compartment, early tumors may be asymptomatic and discovered during routine eye exams. When symptoms occur, they are usually related to the tumor’s size, location, or effects on surrounding structures.

Visual changes

• Floaters: Small, dark specks that drift across the visual field, caused by tumor debris or vitreous hemorrhage.
• Blurred or reduced vision: May be unilateral; often progressive as the tumor grows.
• Peripheral visual field loss: A “shadow” or curtain effect, especially with peripheral tumors.
• Metamorphopsia: Distorted vision, straight lines appear wavy.
• Reduced color perception: Particularly if the macula (central retina) is involved.

Pain and ocular discomfort

• Eye pain: Uncommon for small tumors but can occur if the tumor invades adjacent structures.
• Redness or photophobia: May accompany secondary inflammation.

Physical signs observed by an eye specialist

• Visible pigmented lesion: Dark, dome‑shaped mass seen on ophthalmoscopy.
• Sub‑retinal fluid: Accumulation of fluid under the retina causing a “shallow retinal detachment.”
• Rapid growth: Noted on serial eye exams.

Causes and Risk Factors

The exact cause of uveal melanoma remains uncertain, but several factors increase risk:

Genetic predisposition

• Familial melanoma syndromes: Mutations in the CDKN2A or BAP1 genes raise risk for uveal and cutaneous melanoma.
• BAP1 tumor predisposition syndrome: Associated with earlier onset and higher metastatic potential.

Phenotypic factors

• Light eye color: Blue or green irises have a higher incidence than brown eyes.
• Fair skin: Low melanin protection may increase susceptibility to UV‑induced DNA damage.
• Freckles or ocular melanocytosis: Congenital over‑pigmentation of the uveal tract.

Environmental exposures

• Ultraviolet (UV) radiation: The role is controversial; epidemiologic data suggest a modest link, especially with intense intermittent sun exposure.
• Ionizing radiation: Prior therapeutic radiation to the head/neck region.

Other risk modifiers

• Age: Incidence rises sharply after age 40.
• Male sex: Slightly higher rates.
• Geographic location: Higher rates in northern Europe and North America, likely reflecting skin type distribution.

Diagnosis

A prompt, accurate diagnosis is essential because treatment decisions and prognosis are heavily dependent on tumor size, location, and genetics.

Comprehensive eye examination

• Dilated fundus examination: Ophthalmologist uses a slit‑lamp and indirect ophthalmoscopy to visualize the posterior segment.
• Fundus photography: Baseline documentation for monitoring growth.

Imaging studies

• Ultrasound B‑scan (Uvea echography): Determines thickness, internal reflectivity, and vascularity; essential for measuring tumor dimensions.
• Optical coherence tomography (OCT): High‑resolution cross‑sectional images of retina and sub‑retinal fluid.
• Fluorescein angiography (FA) / Indocyanine green angiography (ICGA): Evaluate tumor vasculature and leakage.
• Magnetic resonance imaging (MRI): Preferred for orbital and extra‑ocular extension; helps differentiate melanoma from other lesions.

Biopsy (select cases)

Fine‑needle aspiration biopsy (FNAB) may be performed when:

• Lesion is atypical and the diagnosis is uncertain.
• Genetic profiling is needed for prognostication (e.g., monosomy 3, BAP1 loss).

Systemic staging

• Liver imaging: Contrast‑enhanced CT or MRI of the abdomen; liver is the most common metastatic site.
<
• Blood tests: Liver function panel, lactate dehydrogenase (LDH) as a non‑specific marker.

Prognostic testing

Gene expression profiling (GEP) and chromosomal analysis (e.g., monosomy 3, 8q gain) stratify patients into low‑ vs. high‑risk for metastasis, guiding surveillance intensity.

Treatment Options

Treatment aims to eradicate the primary tumor while preserving vision when possible. Choice depends on tumor size, location, patient age, systemic health, and metastatic status.

Local‑eye therapies

• Plaque brachytherapy: A radioactive (usually Iodine‑125, Ruthenium‑106, or Palladium‑103) silastic plaque is sutured to the sclera overlying the tumor for 3–7 days. Offers high local control (>95 %) with variable visual outcomes.
• External beam radiation therapy (EBRT): Proton beam or stereotactic radiosurgery (e.g., Gamma Knife) for tumors unsuitable for plaque (e.g., large basal diameter, proximity to optic nerve).
• Transpupillary thermotherapy (TTT): Infrared laser heating; often adjunctive after brachytherapy.
• Local resection (partial lamellar sclerouvectomy): Surgical removal of the tumor; reserved for select cases where radiation is contraindicated or for large anterior tumors.
• Enucleation: Removal of the entire eye; indicated for massive tumors, painful blind eye, or when intra‑ocular spread threatens life. Modern orbital implants improve cosmetic outcomes.

Systemic therapies (metastatic disease)

Metastatic uveal melanoma responds poorly to conventional cutaneous‑melanoma regimens. Approved and investigational options include:

• Immunotherapy:
  • Checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) have modest response rates (<10 %).
  • Combination regimens are under study.
• Targeted therapy:
  • MEK inhibitors (trametinib, cobimetinib) for tumors with activating GNAQ/GNA11 mutations; limited efficacy.
• Liver‑directed treatments: Chemo‑embolization, radio‑embolization, hepatic arterial infusion pump, and selective internal radiotherapy (SIRT) are used when liver metastases dominate.
• Clinical trials: Novel agents (e.g., tebentafusp, a bispecific T‑cell engager) have shown promising survival benefits and are FDA‑approved for HLA‑A*02:01‑positive patients (2022). Enrollment should be discussed early.

Supportive and lifestyle measures

• Regular ophthalmologic follow‑up to monitor for local recurrence.
• Low‑salt diet and alcohol moderation to protect liver function if hepatic metastases develop.
• Psychological counseling, support groups, and vision rehabilitation services.

Living with Uvea Melanoma

Adapting to life after diagnosis involves medical, visual, and emotional considerations.

Vision management

• Low‑vision aids: Magnifiers, high‑contrast reading glasses, and electronic devices improve daily functioning.
• Occupational therapy: Tailors home and work environments for safety (e.g., good lighting, reduced glare).
• Regular eye exams: At least every 6 months for the first 2 years, then annually, to detect recurrence or new lesions.

Follow‑up schedule

Based on risk stratification:

• Low‑risk (Class 1 GEP): Liver MRI/CT every 6–12 months.
• High‑risk (Class 2 GEP, monosomy 3): Liver imaging every 3–6 months; consider serum biomarkers (e.g., S-100, MIA) though they are not definitive.

Emotional health

• Join melanoma‑specific support groups (e.g., Melanoma Research Foundation).
• Consider counseling or psychotherapy to cope with anxiety about metastasis.
• Mind‑body techniques (meditation, yoga) can improve quality of life.

Lifestyle recommendations

• Sun protection: Broad‑spectrum sunscreen (SPF 30+) on eyelids and face; UV‑blocking sunglasses.
• Balanced diet: Emphasize fruits, vegetables, omega‑3 fatty acids, and adequate hydration; may support overall health.
• Physical activity: Moderate exercise (30 min most days) improves cardiovascular health, which is important for patients undergoing systemic therapy.

Prevention

Because many risk factors (age, genetics) cannot be modified, prevention focuses on reducing environmental contributors and early detection.

• Wear UV‑blocking sunglasses and wide‑brimmed hats outdoors.
• Avoid tanning beds and limit intense midday sun exposure.
• Undergo comprehensive dilated eye exams at least once every 2 years after age 40, or annually if you have known risk factors (light eye color, family history, ocular melanocytosis).
• Inform your ophthalmologist of any personal or family history of melanoma.
• Discuss genetic counseling if you carry mutations in BAP1, CDKN2A, or related genes.

Complications

If left untreated or if metastasis occurs, several serious complications may develop:

• Vision loss: Progressive retinal detachment, macular involvement, or optic nerve compression.
• Secondary glaucoma: Tumor invasion or treatment‑related inflammation can raise intra‑ocular pressure.
• Enucleation: Loss of the eye, leading to cosmetic and psychosocial impacts.
• Liver failure: Metastatic spread to the liver is common (≈80 % of metastatic cases) and can lead to hepatic insufficiency, ascites, and coagulopathy.
• Systemic cachexia and fatigue: Often seen in advanced disease.
• Psychological distress: Anxiety, depression, and decreased quality of life are prevalent.

When to Seek Emergency Care

For non‑emergent concerns, contact your ophthalmologist or oncology team promptly.

---

Sources: Mayo Clinic, National Cancer Institute (NCI), American Academy of Ophthalmology, CDC, World Health Organization, Cleveland Clinic, SEER Cancer Statistics (2022), BAP1 Cancer Predisposition Consortium, FDA prescribing information for tebentafusp (2022).